Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) had its target price raised by Argus from $42.00 to $50.00 in a research report issued to clients and investors on Tuesday, Benzinga reports. The brokerage currently has a "buy" rating on the stock. Argus's price objective would suggest a potential upside of 19.39% from the company's current price.
Several other brokerages have also recently issued reports on TEVA. Weiss Ratings upgraded Teva Pharmaceutical Industries from a "hold (c)" rating to a "hold (c+)" rating in a research note on Wednesday, November 4th. TD Cowen raised their price objective on Teva Pharmaceutical Industries from $55.00 to $57.00 and gave the stock a "buy" rating in a research note on Wednesday, November 4th. Leerink Partners lifted their price objective on Teva Pharmaceutical Industries from $45.00 to $52.00 and gave the company an "outperform" rating in a report on Thursday, November 5th. HC Wainwright reiterated a "buy" rating and set a $54.00 target price on shares of Teva Pharmaceutical Industries in a research report on Tuesday. Finally, JPMorgan Chase & Co. increased their target price on Teva Pharmaceutical Industries from $40.00 to $50.00 and gave the stock an "overweight" rating in a report on Monday, October 12th. Fourteen analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Teva Pharmaceutical Industries currently has an average rating of "Moderate Buy" and an average price target of $48.43.
Check Out Our Latest Research Report on TEVA
Teva Pharmaceutical Industries Stock Performance
Teva Pharmaceutical Industries stock traded down $0.69 during midday trading on Tuesday, hitting $41.88. The company's stock had a trading volume of 1,742,121 shares, compared to its average volume of 6,841,446. The company has a debt-to-equity ratio of 1.59, a current ratio of 0.95 and a quick ratio of 0.74. The company has a market cap of $48.80 billion, a price-to-earnings ratio of 97.40, a PEG ratio of 4.09 and a beta of 0.97. Teva Pharmaceutical Industries has a 1-year low of $24.01 and a 1-year high of $44.57. The company has a 50-day moving average price of $40.29 and a two-hundred day moving average price of $35.12.
Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last announced its earnings results on Tuesday, November 3rd. The company reported $0.86 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.72 by $0.14. Teva Pharmaceutical Industries had a net margin of 2.94% and a return on equity of 33.20%. The firm had revenue of $4.39 billion for the quarter, compared to analyst estimates of $4.23 billion. During the same quarter in the prior year, the business posted $0.78 EPS. The business's revenue was down 1.9% compared to the same quarter last year. As a group, sell-side analysts predict that Teva Pharmaceutical Industries will post 1.98 earnings per share for the current year.
Insider Buying and Selling at Teva Pharmaceutical Industries
In other news, insider Brian Savage sold 7,342 shares of the firm's stock in a transaction that occurred on Friday, September 18th. The shares were sold at an average price of $38.85, for a total value of $285,236.70. Following the sale, the insider directly owned 8,500 shares in the company, valued at approximately $330,225. This trade represents a 46.35% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Richard D. Francis sold 250,000 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Tuesday, November 10th. The shares were sold at an average price of $42.24, for a total transaction of $10,560,000.00. Following the sale, the chief executive officer directly owned 927,529 shares in the company, valued at $39,178,824.96. This trade represents a 21.23% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 715,945 shares of company stock worth $29,061,351 over the last quarter. 0.54% of the stock is currently owned by company insiders.
Hedge Funds Weigh In On Teva Pharmaceutical Industries
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Parallel Advisors LLC grew its stake in shares of Teva Pharmaceutical Industries by 8.7% during the third quarter. Parallel Advisors LLC now owns 4,626 shares of the company's stock worth $183,000 after buying an additional 370 shares during the last quarter. Envestnet Portfolio Solutions Inc. increased its holdings in shares of Teva Pharmaceutical Industries by 7.1% during the second quarter. Envestnet Portfolio Solutions Inc. now owns 7,311 shares of the company's stock worth $248,000 after buying an additional 483 shares in the last quarter. First Trust Advisors LP lifted its stake in shares of Teva Pharmaceutical Industries by 5.9% in the 1st quarter. First Trust Advisors LP now owns 9,619 shares of the company's stock valued at $290,000 after acquiring an additional 539 shares during the last quarter. EverSource Wealth Advisors LLC lifted its stake in shares of Teva Pharmaceutical Industries by 64.0% in the 1st quarter. EverSource Wealth Advisors LLC now owns 1,658 shares of the company's stock valued at $50,000 after acquiring an additional 647 shares during the last quarter. Finally, Victrix Investment Advisors boosted its holdings in shares of Teva Pharmaceutical Industries by 9.5% during the 2nd quarter. Victrix Investment Advisors now owns 7,850 shares of the company's stock valued at $266,000 after acquiring an additional 681 shares in the last quarter. Institutional investors own 54.05% of the company's stock.
About Teva Pharmaceutical Industries
(
Get Free Report)
Teva Pharmaceutical Industries is a global pharmaceutical company that develops, manufactures and markets generic medicines, specialty medicines and biosimilars. Its portfolio spans treatments for conditions including neurological disorders, respiratory diseases and cancer, alongside a broad range of generic medicines across therapeutic areas. Founded in Jerusalem in 1901, Teva has grown from a regional pharmaceutical business into an international company. It serves patients and healthcare providers in markets around the world, including North America, Europe and other regions.
See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Teva Pharmaceutical Industries, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Teva Pharmaceutical Industries wasn't on the list.
While Teva Pharmaceutical Industries currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.